NCT05886920招募中1 期
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd19 个研究点 分布在 4 个国家目标入组 67 人开始时间: 2023年7月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 67
- 试验地点
- 19
- 主要终点
- Number of Participants With Adverse Events (AEs)
研究概览
简要总结
This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Part 1: Subjects must have a histologically or cytologically confirmed metastatic or locally advanced solid tumor with evidence of progressive disease.
- •Part 2: Subjects must have a histologically or cytologically confirmed metastatic or locally advanced non-small cell lung cancer with evidence of PD.
- •Subjects with non-small cell lung cancer (NSCLC) should have no known epidermal growth factor receptor (EGFR) mutations, ALK/ROS1/RET rearrangements, NTRK1/2/3 gene fusions, v-Raf murine sarcoma viral oncogene homolog B (BRAF) V600E mutations, or MET exon 14 skipping mutations.
- •Note: EGFR mutations include but are not limited to EGFR Exon19 Deletions, Exon21 p.L858R, Exon21 p.L861Q, Exon18 p.G719X, Exon20 p.S768I, Exon20 Insertions, Exon20 p.T790M. If other EGFR mutations are present, the Investigator should have a consultation with the sponsor's Medical Monitor before making the enrollment decision.
- •Part1: Subjects must have documented mitogen-activated protein kinase (MAPK) pathway mutation(s) within the last 5 years identified by a local test on tumor tissue or blood (eg, rat sarcoma (RAS), rapidly accelerated fibrosarcoma (RAF), and MAPK kinase (MAPKK) mutations).
- •Part 2: Subject must have documented Kirsten rat sarcoma viral oncogene (KRAS) p. glycine 12 to cysteine (p.G12C) mutation identified within the last 5 years by a local test on tumor tissue or blood.
- •All the local tests should clearly distinguish KRAS p.G12C from all other KRAS p.G12x variants. If not specified, subjects should have no known second KRAS mutations (including G12A, G12V, G12R, G13C, G12D, G12S, H95, Y96, Q61, and R68).
- •Part 1: Subjects must be refractory to or intolerable with standard treatment, or have no available standard of care (SOC).
- •Part 2: Subject must have received at least 1 line of prior standard of care systemic therapy for locally advanced and unresectable or metastatic disease, including KRAS p.G12C inhibitor.
- •Subjects should only have received 1 type of prior KRAS p.G12Ci treatment (including all types of KRAS p.G12C inhibitor which are either under investigation or in market, except D3S-001).
- •During the prior KRAS p.G12C treatment, subject has achieved best response of partial or complete response regardless of KRAS p.G12Ci treatment duration, or stable disease for at least 6 months. However, subjects, who have stopped KRAS p.G12Ci therapy earlier than 6 months due to safety/tolerability reasons only, would be allowed. In such a situation, the Investigator should have a consultation with the Sponsor Medical Monitor before making the enrollment decision.
- •Part 2: Subjects must have measurable disease per RECIST v1.
- •Part 2: Subjects must agree to provide archival tumor tissue, if available, for genetic analysis. If archival tumor tissue is not available, or of insufficient quantity, an optional fresh biopsy is highly recommended.
- •Part 2: Subjects must agree to provide blood samples for genetic analysis (Table 2 schedule of activities for Part 2).
- •Subject must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Subject must have adequate organ and marrow function within the screening period.
- •Subjects must comply with all reproductive and contraceptive requirements outlined in the protocol.
排除标准
- •Subject has any prior treatment with other treatments without adequate washout periods as defined in the protocol.
- •Part 2: subjects with mixed small-cell lung cancer, or large cell neuroendocrine histology, or sarcomatoid carcinoma.
- •Subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.
- •Part 1: Uncontrolled or untreated brain metastasis.
- •Part 2: Asymptomatic and stable brain metastases subjects will be eligible for enrollment per the following criteria.
- •Treated or untreated brain metastases
- •Neurologically asymptomatic
- •Stable and not requiring steroids more than 10 mg/day of prednisone or equivalent for at least 4 weeks prior to the first dose of study medication.
- •Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade ≥2 (with exception of vitiligo or alopecia).
- •Subject has active gastrointestinal disease or other that could interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.
- •Any concurrent chemotherapy, immunotherapy, targeted therapy, cell therapy, biologic or hormonal therapy and any medical devices for cancer treatment.
- •NOTE: Other protocol inclusion/exclusion criteria may apply
研究组 & 干预措施
D3S-002 and D3S-001 Combination Therapy
Experimental
Part 2a: Dose Escalation, D3S-002 and D3S-001 administered orally.
Part 2b: Dose Expansion, D3S-002 and D3S-001 administered orally.
干预措施: D3S-001 (Drug)
D3S-002 Monotherapy
Experimental
Part 1: Dose Escalation, D3S-002 administered orally.
干预措施: D3S-002 (Drug)
D3S-002 and D3S-001 Combination Therapy
Experimental
Part 2a: Dose Escalation, D3S-002 and D3S-001 administered orally.
Part 2b: Dose Expansion, D3S-002 and D3S-001 administered orally.
干预措施: D3S-002 (Drug)
结局指标
主要结局
Number of Participants With Adverse Events (AEs)
时间窗: First dose until 30 days after the last dose (or specified in the protocol)
Number of Participants With Adverse Events (AEs)
时间窗: First dose until 30 days after the last dose (or specified in the protocol)
Maximum tolerated dose (MTD) based on Dose limiting toxicities (DLTs)
时间窗: First dose up to 24 months
Recommended Phase 2 dose (RP2D)
时间窗: First dose up to 24 months
次要结局
- Objective response rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)(Until disease progression or end of treatment (up to approximately 24 months))
- Disease control rate (DCR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)(Until disease progression or end of treatment (up to approximately 24 months))
- Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)(Until disease progression or end of treatment (up to approximately 24 months))
- Part 1: D3S-002 maximum observed plasma concentration (Cmax)(First dose up to 24 months)
- Part 2: D3S-002 and D3S-001 maximum observed plasma concentration (Cmax)(First dose up to 24 months)
- Part 1: D3S-002 time to maximum plasma concentration (tmax)(First dose up to 24 months)
- Part 2: D3S-002 and D3S-001 time to maximum plasma concentration (tmax)(First dose up to 24 months)
- Part 1: D3S-002 half-life (t1/2)(First dose up to 24 months)
- Part 2: D3S-002 and D3S-001 half-life (t1/2)(First dose up to 24 months)
- Part 1: D3S-002 area under the concentration-time curve (AUC)(First dose up to 24 months)
- Part 2: D3S-002 and D3S-001 area under the concentration-time curve (AUC)(First dose up to 24 months)
- Objective response rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)(Until disease progression or end of treatment (up to approximately 24 months))
- Disease control rate (DCR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)(Until disease progression or end of treatment (up to approximately 24 months))
- Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)(Until disease progression or end of treatment (up to approximately 24 months))
研究者
研究点 (19)
Loading locations...
相似试验
已完成
1 期
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid TumorsSolid TumorNCT04547205Akeso40
已完成
1 期
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate AccumulationsAdvanced Solid Tumor MalignancyNCT04260529Cytovation AS60
尚未招募
1 期
A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 AlterationsSolid Tumors With FGFR2 Alterations, AdultNCT062879183H (Suzhou) Pharmaceuticals Co., Ltd.130
Unknown
1 期
Clinical Study of JS201 in Patients With Advanced Malignant TumorsPatients With Advanced Malignant TumorsNCT04956926Shanghai Junshi Bioscience Co., Ltd.244
终止
1 期
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHLNon-Hodgkins LymphomaChronic Lymphocytic LeukemiaNCT04240704Novartis Pharmaceuticals25